IL154949A0 - Imidazole derivatives as raf kinase inhibitors - Google Patents
Imidazole derivatives as raf kinase inhibitorsInfo
- Publication number
- IL154949A0 IL154949A0 IL15494901A IL15494901A IL154949A0 IL 154949 A0 IL154949 A0 IL 154949A0 IL 15494901 A IL15494901 A IL 15494901A IL 15494901 A IL15494901 A IL 15494901A IL 154949 A0 IL154949 A0 IL 154949A0
- Authority
- IL
- Israel
- Prior art keywords
- kinase inhibitors
- raf kinase
- imidazole derivatives
- migraine
- pain
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 102000009929 raf Kinases Human genes 0.000 title abstract 2
- 108010077182 raf Kinases Proteins 0.000 title abstract 2
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000006726 chronic neurodegeneration Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0023197A GB0023197D0 (en) | 2000-09-21 | 2000-09-21 | Compounds |
| GB0023193A GB0023193D0 (en) | 2000-09-21 | 2000-09-21 | Compounds |
| GB0023196A GB0023196D0 (en) | 2000-09-21 | 2000-09-21 | Compouds |
| GB0023208A GB0023208D0 (en) | 2000-09-21 | 2000-09-21 | Compounds |
| PCT/GB2001/004195 WO2002024680A1 (en) | 2000-09-21 | 2001-09-19 | Imidazole derivatives as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL154949A0 true IL154949A0 (en) | 2003-10-31 |
Family
ID=27447885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15494901A IL154949A0 (en) | 2000-09-21 | 2001-09-19 | Imidazole derivatives as raf kinase inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7199137B2 (zh) |
| EP (1) | EP1318992B1 (zh) |
| JP (1) | JP2004509882A (zh) |
| KR (1) | KR20030030027A (zh) |
| CN (1) | CN1471523A (zh) |
| AT (1) | ATE300529T1 (zh) |
| AU (1) | AU2001287901A1 (zh) |
| BR (1) | BR0114023A (zh) |
| CA (1) | CA2423154A1 (zh) |
| CY (1) | CY1105251T1 (zh) |
| CZ (1) | CZ2003793A3 (zh) |
| DE (1) | DE60112312T2 (zh) |
| DK (1) | DK1318992T3 (zh) |
| ES (1) | ES2242767T3 (zh) |
| HU (1) | HUP0301181A2 (zh) |
| IL (1) | IL154949A0 (zh) |
| MX (1) | MXPA03002449A (zh) |
| NO (1) | NO20031270L (zh) |
| PL (1) | PL361397A1 (zh) |
| PT (1) | PT1318992E (zh) |
| WO (1) | WO2002024680A1 (zh) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0015532A (pt) | 1999-11-22 | 2002-06-25 | Smithkline Beecham Plc | Compostos |
| ES2218391T3 (es) * | 2000-03-06 | 2004-11-16 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de raf-cinasa. |
| ATE365730T1 (de) | 2000-11-20 | 2007-07-15 | Smithkline Beecham Corp | Neuartige verbindungen |
| GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| WO2003022832A1 (en) * | 2001-09-05 | 2003-03-20 | Smithkline Beecham P.L.C. | Pyridylfurans and pyrroles as raf kinase inhibitors |
| GB0121490D0 (en) * | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
| WO2003022837A1 (en) * | 2001-09-05 | 2003-03-20 | Smithkline Beecham P.L.C. | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| GB0121488D0 (en) * | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| WO2003086467A1 (en) * | 2002-04-08 | 2003-10-23 | Smithkline Beecham Corporation | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
| US20040132726A1 (en) * | 2002-08-09 | 2004-07-08 | Astrazeneca Ab And Nps Pharmaceuticals, Inc. | New compounds |
| RU2352568C9 (ru) | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
| WO2004014902A2 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| AU2003257329C1 (en) | 2002-08-19 | 2010-07-22 | Lorus Therapeutics Inc. | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents |
| UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| US20090264494A1 (en) * | 2002-10-18 | 2009-10-22 | Board Of Regents, The University Of Texas System | Use of neuroprotective 3-substituted indolone compositions |
| US20050250837A1 (en) * | 2002-10-18 | 2005-11-10 | D Mello Santosh R | Use of C-Raf inhibitors for the treatment of neurodegenerative diseases |
| BRPI0409409A (pt) * | 2003-04-14 | 2006-04-25 | Novartis Ag | métodos para tratar doenças proliferativas e para monitorar a eficácia de tratamento de doenças proliferativas |
| US7569593B2 (en) * | 2003-10-02 | 2009-08-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| WO2006126177A2 (en) | 2005-05-25 | 2006-11-30 | Genesense Technologies Inc. | 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer |
| WO2007033187A2 (en) | 2005-09-12 | 2007-03-22 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| US9957569B2 (en) * | 2005-09-12 | 2018-05-01 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
| CN103233063A (zh) * | 2006-11-08 | 2013-08-07 | 密歇根大学董事会 | 前列腺癌标志物spink1及其应用 |
| US7998957B2 (en) | 2007-02-06 | 2011-08-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
| EP2162445B1 (en) | 2007-06-05 | 2013-11-27 | Takeda Pharmaceutical Company Limited | Heterobicyclic compounds as kinase inhibitors |
| JP5433572B2 (ja) * | 2007-07-06 | 2014-03-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｍｉｐｏｌ１−ｅｔｖ１遺伝子再編成 |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| EP2181987B9 (en) | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| US8344135B2 (en) | 2007-08-29 | 2013-01-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| CA2700857C (en) | 2007-10-01 | 2016-08-02 | John S. Kovach | Hdac inhibitors |
| CA2730148C (en) | 2008-08-01 | 2018-04-03 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
| US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| WO2010064611A1 (ja) | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| WO2011034906A2 (en) * | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| WO2011085269A1 (en) * | 2010-01-08 | 2011-07-14 | Selexagen Therapeutics, Inc. | Raf kinase inhibitors |
| US8945556B2 (en) | 2010-11-19 | 2015-02-03 | The Regents Of The University Of Michigan | RAF gene fusions |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| CN103159735B (zh) * | 2011-12-10 | 2015-12-09 | 通化济达医药有限公司 | 取代的咪唑激酶抑制剂 |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| WO2014047330A1 (en) * | 2012-09-19 | 2014-03-27 | Jean-Michel Vernier | Novel raf kinase inhibitors |
| US9309247B2 (en) | 2013-03-20 | 2016-04-12 | Lorus Therapeutics Inc. | 2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer |
| CA2909160C (en) | 2013-04-09 | 2021-05-25 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| KR20160058960A (ko) | 2013-10-04 | 2016-05-25 | 압토스 바이오사이언시스 인코포레이티드 | 암을 치료하기 위한 조성물과 방법 |
| AU2018360477A1 (en) | 2017-10-30 | 2020-06-04 | Aptose Biosciences Inc. | Aryl imidazoles for the treatment of cancer |
| CN108484587A (zh) * | 2018-06-03 | 2018-09-04 | 刘思良 | 一种Raf激酶抑制剂及其在癌症治疗中的应用 |
| WO2022249192A1 (en) * | 2021-05-27 | 2022-12-01 | Ramot At Tel-Aviv University Ltd. | Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| WO1995003297A1 (en) | 1993-07-21 | 1995-02-02 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
| US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| US6342510B1 (en) | 1995-06-12 | 2002-01-29 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| JP2000504023A (ja) | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | 癌治療方法 |
| ES2239357T3 (es) | 1996-06-10 | 2005-09-16 | MERCK & CO., INC. | Imidazoles sustituidos que tienen actividad inhibidora de citoquinas. |
| WO1997048672A2 (en) | 1996-06-21 | 1997-12-24 | Allergan Sales, Inc. | Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| DE69729946T2 (de) | 1996-10-15 | 2005-01-20 | G.D. Searle Llc | Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia |
| JP3292478B2 (ja) | 1996-10-30 | 2002-06-17 | シェーリング コーポレイション | ニューロキニンアンタゴニストとしてのピペラジノ誘導体 |
| CA2302417A1 (en) | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Adenosine a3 receptor antagonists |
| AU1053399A (en) | 1997-11-14 | 1999-06-07 | Sankyo Company Limited | Pyridylpyrrole derivatives |
| AU5247599A (en) | 1998-07-30 | 2000-02-21 | Point Biomedical Corporation | A novel excipient for the lyophilization of aqueous suspensions of microparticles |
-
2001
- 2001-09-19 DE DE60112312T patent/DE60112312T2/de not_active Expired - Fee Related
- 2001-09-19 KR KR10-2003-7004109A patent/KR20030030027A/ko not_active Application Discontinuation
- 2001-09-19 AT AT01967528T patent/ATE300529T1/de not_active IP Right Cessation
- 2001-09-19 DK DK01967528T patent/DK1318992T3/da active
- 2001-09-19 PL PL01361397A patent/PL361397A1/xx not_active Application Discontinuation
- 2001-09-19 CZ CZ2003793A patent/CZ2003793A3/cs unknown
- 2001-09-19 CN CNA018182135A patent/CN1471523A/zh active Pending
- 2001-09-19 BR BR0114023-0A patent/BR0114023A/pt not_active Application Discontinuation
- 2001-09-19 WO PCT/GB2001/004195 patent/WO2002024680A1/en active IP Right Grant
- 2001-09-19 MX MXPA03002449A patent/MXPA03002449A/es unknown
- 2001-09-19 AU AU2001287901A patent/AU2001287901A1/en not_active Abandoned
- 2001-09-19 ES ES01967528T patent/ES2242767T3/es not_active Expired - Lifetime
- 2001-09-19 HU HU0301181A patent/HUP0301181A2/hu unknown
- 2001-09-19 PT PT01967528T patent/PT1318992E/pt unknown
- 2001-09-19 EP EP01967528A patent/EP1318992B1/en not_active Expired - Lifetime
- 2001-09-19 CA CA002423154A patent/CA2423154A1/en not_active Abandoned
- 2001-09-19 US US10/380,891 patent/US7199137B2/en not_active Expired - Fee Related
- 2001-09-19 IL IL15494901A patent/IL154949A0/xx unknown
- 2001-09-19 JP JP2002529090A patent/JP2004509882A/ja active Pending
-
2003
- 2003-03-19 NO NO20031270A patent/NO20031270L/no not_active Application Discontinuation
-
2005
- 2005-09-06 CY CY20051101069T patent/CY1105251T1/el unknown
-
2007
- 2007-01-22 US US11/625,406 patent/US20070135433A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20031270D0 (no) | 2003-03-19 |
| HUP0301181A2 (en) | 2007-02-28 |
| US7199137B2 (en) | 2007-04-03 |
| EP1318992A1 (en) | 2003-06-18 |
| CY1105251T1 (el) | 2010-03-03 |
| US20070135433A1 (en) | 2007-06-14 |
| CZ2003793A3 (cs) | 2004-04-14 |
| ES2242767T3 (es) | 2005-11-16 |
| PL361397A1 (en) | 2004-10-04 |
| BR0114023A (pt) | 2004-02-03 |
| DE60112312T2 (de) | 2005-12-29 |
| PT1318992E (pt) | 2005-11-30 |
| CA2423154A1 (en) | 2002-03-28 |
| NO20031270L (no) | 2003-05-19 |
| DK1318992T3 (da) | 2005-11-21 |
| CN1471523A (zh) | 2004-01-28 |
| MXPA03002449A (es) | 2003-06-19 |
| JP2004509882A (ja) | 2004-04-02 |
| KR20030030027A (ko) | 2003-04-16 |
| AU2001287901A1 (en) | 2002-04-02 |
| US20040038964A1 (en) | 2004-02-26 |
| EP1318992B1 (en) | 2005-07-27 |
| WO2002024680A1 (en) | 2002-03-28 |
| DE60112312D1 (de) | 2005-09-01 |
| ATE300529T1 (de) | 2005-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL154949A0 (en) | Imidazole derivatives as raf kinase inhibitors | |
| GB0121490D0 (en) | Ciompounds | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| ZA200500323B (en) | Use of lkb kinase inhibitors for the treatment of pain. | |
| WO2003080582A3 (de) | Fredericamycin-derivate | |
| IL172942A0 (en) | Pyrazoloisoquinoline derivatives as kinase inhibitors | |
| MXPA05013349A (es) | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| AU2003226572A1 (en) | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | |
| TW200801008A (en) | Protein kinase inhibitors | |
| MXPA03010134A (es) | Derivados de ciclohexan-1-4-diamina sustituidos. | |
| MY135477A (en) | 2-(2,6-dichlorophenyl)-diarylimidazoles | |
| TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| IL178261A0 (en) | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer | |
| MY148617A (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
| WO2003039545A3 (en) | Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers | |
| AU2001292579A1 (en) | Methods and compounds for treating proliferative diseases | |
| WO2003028721A3 (en) | Substituted benzimidazole compounds and their use for the treatment of cancer | |
| GB0121494D0 (en) | Compounds | |
| DE60328603D1 (de) | Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren | |
| TR200002203T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
| WO2005021510A3 (en) | Benzimidazole c-2 heterocycles as kinase inhibitors | |
| MXPA04000272A (es) | Derivados de 4-aminociclohexanol sustituidos. | |
| TW200602023A (en) | Monocyclic heterocycles as kinase inhibitors |